Online inquiry

IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ5123MR)

This product GTTS-WQ5123MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL1RAP gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 0
Species	Humanized
RefSeq	NM_001167928.2
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	3556
UniProt ID	Q9NPH3

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5123MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ3780MR	IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	BAY-86-6150
GTTS-WQ11463MR	IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	MEHD7945A
GTTS-WQ3932MR	IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	BCD-145
GTTS-WQ42MR	IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, Pseudo-UTP, 120 nt-poly(A))	mRNA	2857916
GTTS-WQ5679MR	IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	CDX-011 (DOX)
GTTS-WQ2689MR	IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	AMG 785
GTTS-WQ4947MR	IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	c13C6-FR1-N
GTTS-WQ10697MR	IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	M-1095

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST